Back to Journals » OncoTargets and Therapy » Volume 11

MicroRNA-1225-5p behaves as a tumor suppressor in human glioblastoma via targeting of IRS1

Authors Li D, Chi G, Chen Z, Jin X

Received 22 June 2018

Accepted for publication 4 September 2018

Published 28 September 2018 Volume 2018:11 Pages 6339—6350

DOI https://doi.org/10.2147/OTT.S178001

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Dongyuan Li, Guonan Chi, Zhuo Chen, Xingyi Jin

First Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, People’s Republic of China

Background: MicroRNAs (miRNAs) play an important role in cancer initiation, progression, and metastasis by directly regulating their target genes.
Materials and methods: In this study, we observed that the miR-1225-5p expression level in glioblastoma tissues was significantly lower as compared with that in normal brain tissues, and its low expression was significantly associated with histopathological grade and poor patient prognosis.
Results: Through establishing a miR-1225-5p overexpression glioblastoma cell line, we found that ectopic overexpression of miR-1225-5p inhibited the proliferation, migration, and invasion of glioblastoma cells in vitro. Moreover, the growth of a glioblastoma xenograft tumor was attenuated by overexpression of miR-1225-5p. Further integrative studies suggested that the insulin receptor substrate 1 (IRS1) was a direct functional target of miR-1225-5p in glioblastoma, and the mRNA and protein levels of IRS1 in six human glioblastoma cell lines (A172, SW1783, U87, LN-229, SW1088, and T98G) were significantly higher as compared with normal human astrocytes.
Conclusion: These results suggest that miR-1225-5p may be a novel candidate for glioblastoma therapy.

Keywords: microRNA, microRNA-1225-5p, glioblastoma, insulin receptor substrate 1, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]